Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | RXRB | P28702 | 1/20 | 0.33 |
| ▸ | IDH1 | O75874 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | RARB | P10826 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18308733 | 0.91 | ALDH1A1 (0.35) | ALDH1A1CYP3A4TSHRTDP1RARB | |
| SCHEMBL18308789 | 0.91 | ALDH1A1 (0.35) | ALDH1A1CYP3A4TSHRTDP1RARB | |
| SCHEMBL18308777 | 0.88 | HSD17B1 (0.39) | IDH1CYP3A4 | |
| SCHEMBL20382346 | 0.86 | RXRA (0.41) | RXRARXRBIDH1NPC1RAB9A | |
| SCHEMBL18308772 | 0.84 | ALDH1A1 (0.33) | RXRARXRBALDH1A1CYP3A4TSHR | |
| SCHEMBL18308783 | 0.84 | RXRA (0.37) | RXRARXRBALDH1A1CYP3A4TSHR | |
| SCHEMBL18308751 | 0.83 | ESR1 (0.34) | ALDH1A1CYP3A4TSHRTDP1RARB | |
| SCHEMBL18308746 | 0.82 | ALDH1A1 (0.34) | RXRARXRBALDH1A1CYP3A4TSHR | |
| SCHEMBL18308782 | 0.82 | RXRA (0.36) | RXRARXRBIDH1NPC1RAB9A | |
| SCHEMBL18621838 | 0.81 | RXRA (0.39) | RXRARXRBIDH1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718791-B2 | Polymerisable compounds and the use thereof in liquid-crystal displays | MERCK PATENT GMBH (DE) | 2023-08-08 | — | — | US | disclosed |
| US-20170121606-A1 | POLYMERIZABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS | GMBH, MERCK PATENT (DE) | 2017-05-04 | — | — | US | disclosed |
| US-20160362606-A1 | POLYMERIZABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS | MERCK PATENT GMBH (DE) | 2016-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718791-B2 | Polymerisable compounds and the use thereof in liquid-crystal displays | VCL, ILK, LCP1 | RXRA 2691/4885RXRB 3380/4885IDH1 3934/4885 |
| US-20170121606-A1 | POLYMERIZABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS | VCL, LCP1, MAP1LC3C | RXRA 1974/4885RXRB 2761/4885IDH1 4468/4885 |
| US-20160362606-A1 | POLYMERIZABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS | VCL, PLEC, EML4 | RXRA 2009/4885RXRB 2698/4885IDH1 4422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.